Gravity Analytica

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CYTK 11.04.2024

SERA-AI Powered Highlights

Drug:aficamten-001 aficamten

Drug:omecamtiv-002 omecamtiv mecarbil

Drug:CK586-003 CK-586

Diseases:obstructive hypertrophic cardiomyopathy (HCM)

Diseases:non-obstructive hypertrophic cardiomyopathy

Diseases:pediatric obstructive hypertrophic cardiomyopathy

Diseases:heart failure

Diseases:heart failure with preserved ejection fraction (HFpEF)

Full Press Release SEC Filings Our CYTK Tweets

About Gravity Analytica

Recent Filings

SOUTH SAN FRANCISCO, Calif.,Nov. 04, 2024(GLOBE NEWSWIRE) --Cytokinetics, Incorporated(Nasdaq: CYTK) today announced that onOctober 31, 2024it granted stock options to purchase an aggregate of 17,712 shares of common stock and 11,499 restricted stock units (RSUs) that will be settled into shares of common stock upon vesting to 7 employees, whose employment commenced inOctober 2024, as a material inducement to their employment.

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee’s continued service with the Company. The stock options that were granted are subject to an exercise price of$51.00per share, which is equal to the closing price of the Company’s common stock onOctober 31, 2024, and will vest over 4 years, with 1/4^thof the shares underlying the employee’s option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee’s continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

AboutCytokinetics

Cytokineticsis a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial evaluatingaficamten,a next-in-class cardiac myosin inhibitor, in obstructive hypertrophic cardiomyopathy (HCM),Cytokineticssubmitted an NDA foraficamtento theU.S. Food & Drug Administrationand is progressing regulatory submissions foraficamtenfor the treatment of obstructive HCM inEurope.Aficamtenis also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial ofaficamtenas monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial ofaficamtenin patients with non-obstructive HCM, CEDAR-HCM, a clinical trial ofaficamtenin a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study ofaficamtenin patients with HCM.Cytokineticsis also developingomecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally,Cytokineticsis developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct fromaficamtenfor the potential treatment of heart failure with preserved ejection fraction (HFpEF).

For additional information aboutCytokinetics, visitwww.cytokinetics.comand follow us onX,LinkedIn,FacebookandYouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission particularly under the caption “Risk Factors” in Cytokinetics’ latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and theCYTOKINETICSand C-shaped logo are registered trademarks ofCytokineticsin theU.S.and certain other countries.

Contact:CytokineticsDiane WeiserSenior Vice President, Corporate Affairs(415) 290-7757

Source: Cytokinetics, Incorporated

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com